Disc Medicine (NASDAQ:IRON) COO Jonathan Yen-Wen Yu Sells 300 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $82.53, for a total value of $24,759.00. Following the completion of the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at approximately $4,483,359.72. This represents a 0.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, August 25th, Jonathan Yen-Wen Yu sold 8,796 shares of Disc Medicine stock. The shares were sold at an average price of $83.12, for a total value of $731,123.52.
• On Wednesday, August 12th, Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock. The shares were sold at an average price of $82.64, for a total value of $66,442.56.
• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The stock was sold at an average price of $82.50, for a total value of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The stock was sold at an average price of $72.50, for a total transaction of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The shares were sold at an average price of $72.66, for a total transaction of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The stock was sold at an average price of $69.19, for a total transaction of $1,287,764.28.

Disc Medicine Price Performance

IRON stock opened at $82.67 on Thursday. Disc Medicine, Inc. has a 12 month low of $40.00 and a 12 month high of $99.50. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $76.56 and a 200 day moving average price of $69.95. The stock has a market cap of $316.63 million, a PE ratio of -12.56 and a beta of 1.00.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. Equities research analysts anticipate that Disc Medicine, Inc. will post -6.61 earnings per share for the current year.

Institutional Investors Weigh In On Disc Medicine

Hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System raised its stake in shares of Disc Medicine by 8,273.0% during the 2nd quarter. California State Teachers Retirement System now owns 2,878,790 shares of the company’s stock worth $210,555,000 after acquiring an additional 2,844,408 shares in the last quarter. BlackRock Inc. purchased a new position in Disc Medicine in the second quarter worth $180,502,000. JPMorgan Chase & Co. increased its position in shares of Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after purchasing an additional 828,248 shares in the last quarter. BVF Inc. IL purchased a new stake in shares of Disc Medicine during the 4th quarter valued at $51,616,000. Finally, Jennison Associates LLC purchased a new position in Disc Medicine during the 4th quarter worth $42,252,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IRON has been the subject of a number of research analyst reports. HC Wainwright raised their price target on Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Morgan Stanley reiterated an “overweight” rating and issued a $90.00 price target on shares of Disc Medicine in a report on Monday, August 17th. Wall Street Zen upgraded Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Wedbush reaffirmed an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a research report on Wednesday, June 10th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $106.50.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.